Pentapeptide-18 is a five-amino-acid cosmetic peptide sold under the trade name Leuphasyl. Its sequence is a close copy of leucine-enkephalin, with one D-amino acid swapped in. This guide covers its structure, proposed mechanism, research and regulatory status. Sources were checked on November 17, 2026.
Quick answer: Pentapeptide-18 is a synthetic pentapeptide, Tyr-D-Ala-Gly-Phe-Leu, also known as Leuphasyl. CosIng lists it as a skin conditioning ingredient. Its enkephalin-like mechanism comes from reviews and supplier material, not from independent human trials. We found no CIR safety assessment for it.
Vitrapep does not sell pentapeptide-18; this page is a reference summary of published research and regulatory information.
What is pentapeptide-18?
Pentapeptide-18 is a linear chain of five amino acids with no fatty acid attached. CosIng describes it as “a synthetic peptide consisting of alanine, glycine, leucine, phenylalanine and tyrosine” (CosIng, 2026). PubChem gives the sequence as Tyr-D-Ala-Gly-Phe-Leu, the formula C29H39N5O7 and a molecular weight of 569.6 g/mol (PubChem CID 10099522). Our peptide primer explains the basics.
The sequence explains its design. Leu-enkephalin is a pentapeptide of tyrosine, glycine, glycine, phenylalanine and leucine (PubChem CID 461776). Pentapeptide-18 replaces the second amino acid, glycine, with D-alanine, the mirror-image form of alanine. PubChem lists the synonym “[D-Ala2]leucine-enkephalin” for this reason.
PubChem also lists Leuphasyl as a synonym. A 2024 study states that the Leuphasyl peptide it tested was supplied by Lipotec (Pawłowska et al., 2024).
Pentapeptide-18: key facts
| Fact | Detail |
|---|---|
| INCI name | Pentapeptide-18 |
| Structure type | Linear pentapeptide with one D-amino acid; no fatty acid group |
| Sequence | Tyr-D-Ala-Gly-Phe-Leu ([D-Ala2]leucine-enkephalin) |
| Molecular formula | C29H39N5O7 |
| Molecular weight | 569.6 g/mol |
| Main cosmetic function (CosIng) | Skin conditioning |
| Trade name(s) | Leuphasyl |
How does pentapeptide-18 work?
A 2020 review places pentapeptide-18 among “neurotransmitter inhibitor peptides.” It defines these as peptides that can potentially inhibit release of acetylcholine, a nerve-to-muscle messenger. The review says Leuphasyl “acts like enkephalins,” lowering acetylcholine secretion at the synapse, and cites supplier data for this (Errante et al., 2020).
A 2024 paper adds detail. It says the peptide affects receptors at neuromuscular synapses by binding enkephalin receptors. That binding is described as closing calcium channels and reducing acetylcholine release. The paper cites the 2020 review and Lipotec material for these statements (Pawłowska et al., 2024). We found no independent study that measured this effect in human skin.
The idea resembles that of Argireline, which the same review also classes as a neurotransmitter inhibitor. Another batch guide covers acetyl octapeptide-3 (SNAP-8).
What is pentapeptide-18 used for?
CosIng lists one function for pentapeptide-18: skin conditioning. It appears in cosmetic formulas under its INCI name or as Leuphasyl.
Under US law, intended use decides whether a product is a cosmetic or a drug. Claims to affect the structure or function of the body can make a product a drug (FDA, 2024).
What does the research show?
Peer-reviewed research on pentapeptide-18 is small. We found no placebo-controlled human trial of the peptide on its own.
Retinol and pentapeptide-18 eye cream (human). Polish researchers loaded retinol and pentapeptide-18 into solid lipid nanoparticles. Each of 20 women aged 30 to 65 used two eye creams: one with these particles and a base cream without them. At week 8, the particle cream showed a 20% drop in total wrinkle area versus 11% for the base. Hydration rose 5% with the particle cream (Pawłowska et al., 2024).
Because retinol was also present, the peptide’s own share of any change cannot be separated. Two authors worked for the company that made the creams.
D-tyrosine variant (cell and tissue models). Researchers in Korea added a D-tyrosine to pentapeptide-18. The modified peptide lowered melanin content and tyrosinase activity in MNT-1 melanoma cells and primary human melanocytes. It also reduced melanin in a 3D human skin model (Park et al., 2020). This tested a new variant, not pentapeptide-18 itself.
Computer modeling. A 2026 study combined spectroscopy with docking simulations against signaling proteins such as TNF-α and NF-κB (Akhan et al., 2026). These are predictions, not measurements in skin.
What safety data exist?
We found no Cosmetic Ingredient Review (CIR) safety assessment of pentapeptide-18 in searches of cir-safety.org. CosIng lists no EU restrictions and no SCCS opinion for it.
Published safety data are limited. A second 2026 study from Istanbul researchers found Leuphasyl was not toxic to HaCaT human skin cells in culture (Akhan et al., 2026b). Its toxicity predictions were computer estimates. No human patch-test data for pentapeptide-18 were found in the sources we checked.
Under US law, the responsibility sits with companies. FDA states that “Companies and individuals who manufacture or market cosmetics have a responsibility to ensure the safety of their products” (FDA, 2026).
What is pentapeptide-18’s regulatory status, and how is it used in research?
In the United States, cosmetic products and ingredients, other than color additives, need no FDA approval before sale (FDA, 2025). Pentapeptide-18 is a cosmetic ingredient, not an FDA-approved drug.
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) became law on December 29, 2022. It added facility registration, product listing, serious adverse event reporting, safety substantiation records and mandatory recalls (FDA Voices, 2026). In the EU, CosIng lists pentapeptide-18 with an active status.
In research, pentapeptide-18 has served as a starting scaffold for new variants, as in the D-tyrosine work. It has also been a model active for encapsulation, reaching an encapsulation efficiency of 75.7% in lipid nanoparticles. For the wider class, see peptides in skincare.
Frequently asked questions about pentapeptide-18
Is pentapeptide-18 the same as Leuphasyl?
Leuphasyl is the trade name. PubChem lists it as a synonym of pentapeptide-18.
Is pentapeptide-18 an enkephalin?
It is an analog. It matches leucine-enkephalin except that D-alanine replaces the second glycine.
How does it differ from Argireline?
Both are classed as neurotransmitter-inhibitor peptides. Pentapeptide-18 is described as acting like enkephalins, while Argireline is a different six-amino-acid sequence.
Has CIR reviewed pentapeptide-18?
We found no CIR safety assessment of pentapeptide-18.
Is pentapeptide-18 approved by the FDA?
No. FDA does not approve cosmetic ingredients, other than color additives, before they go on the market.
What to know now
- Structure: Tyr-D-Ala-Gly-Phe-Leu; C29H39N5O7; 569.6 g/mol.
- Design: a leucine-enkephalin analog with D-alanine in position 2.
- Trade name: Leuphasyl.
- Mechanism: described as enkephalin-like; based on reviews and supplier material.
- Evidence: one 20-person study with retinol; cell and computer studies.
- Status: a cosmetic ingredient, not an FDA-approved drug; no CIR review found.
What we’re watching
FDA rules under MoCRA. The MoCRA page, updated October 29, 2026, lists good manufacturing practice and fragrance allergen labeling rules that the law requires. Related guides: Argireline and tripeptide-10 citrulline.